DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Neochem Bio Solutions Limited — Change in Directors/KMP/SMP/Auditor/RTA

NSE 5d ago·25 Aug 2026, 1:17 pm

Neochem Bio Solutions

Neochem Bio Solutions Limited has informed stock exchanges about a significant change in its key management personnel. The company has appointed a new Company Secretary and Compliance Officer, replacing the previous incumbent. Additionally, the firm has updated its Registered Transfer Agent, which is responsible for handling share transfers and investor communications. These changes are routine administrative updates intended to ensure the company's corporate governance and compliance requirements are met.

For investors, this news is primarily procedural and does not signal any operational shifts or financial distress. The replacement of key personnel is a standard part of corporate management. However, it is worth monitoring the company's future disclosures to see if these changes are part of a broader strategic restructuring or if they are simply routine administrative updates. Investors should focus on the company's core business performance rather than this personnel change.